Drug Search Results
More Filters [+]

CFI-402411

Alternative Names: cfi-402411, cfi 402411, cfi402411
Latest Update: 2023-12-15
Latest Update Note: News Article

Product Description

CFI-402411 is a novel, highly orally available immunomodulatory small molecule inhibitor of HPK1 (Hematopoietic Progenitor Kinase 1), a critical regulator of immune cell activation, antigen presentation, and T cell responses to immunosuppressive factors

Mechanisms of Action: HPK1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Treadwell Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CFI-402411

Countries in Clinic: Canada, Hong Kong, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TWT-101

P2

Recruiting

Oncology Solid Tumor Unspecified

2023-12-01

57%

Recent News Events